CHEK1 and head and neck cancer: Investigation of the CHK1 inhibitor LY2603618 (Rabusertib) in head and neck cancer cell lines also found that sensitivity to the drug was dependent on CDK activity, reporting that elevated CDK1 levels were indicative of reduced drug sensitivity, potentially due to up-regulation of origin firing and thus the ability to overcome S phase replication stalling [64].